1 local extension to the adjacent peritoneum and pelvic structures; 2 exfoliation in the abdominal cavity and implantation in multiple peritoneal sites; and 3 lymphatic dissemination, mainly to the pelvic and paraaortic lymph nodes.
Hematogenous dissemination to distant organs (mainly the liver) is much less common [1] . As residual disease (RD) after primary surgery and initial recurrences is usually confined to the peritoneal cavity, i.p. chemotherapy finds its rationale in trying to better control the disease: drugs can reach a higher concentration as well as a longer half-life in the peritoneal cavity [2] [3] [4] [5] . After it was first proposed in 1978 [6] , several trials have tried to compare the efficacy and the safety of different i.p. chemotherapy regimens as opposed to i.v. regimens [7] [8] [9] [10] [11] [12] [13] . Despite trials showing a survival benefit for patients with ovarian cancer (OC) treated by i.p. chemotherapy, not all oncologists agree with this approach [14] . Following the publication of the results of Gynecologic Oncology Group (GOG) 172 in the New England Journal of Medicine [15] , on 4 January 2006, the National Cancer Institute (NCI, Bethesda, MD) posted a statement [16] recommending i.p. chemotherapy as the standard of care for patients with stage III optimally debulked, OC. This has not been universally accepted for many reasons [17] , and several USA and international groups continue to use the combination of i.v. carboplatin area under the curve 5-7.5 mg/ml · min and paclitaxel 175 mg/m 2 as the standard of care [18] . A primary criticism of this regimen resides in the fact that more than half of the patients in GOG 172 who were randomized to the experimental i.p. arm were actually unable to complete their scheduled treatment due to major toxicity.
In January 2006 and reflecting the NCI statement, our practice planned a concerted effort to switch to i.p. chemotherapy adopting the GOG 172 protocol. This included preoperative discussion with patients about the treatment options and placement of an i.p. port at the end of the surgical procedure in cases with RD <1 cm.
The aim of the current study was to evaluate completion rates and toxic effects of a specified i.p. chemotherapy regimen in a cross-section of patients with advanced OC outside the context of a controlled trial to more accurately reflect realworld experience.
patients and methods
An institutional review board approval was obtained for the present study.
patients' data
From January 2006 to December 2007, all patients with stage IIIC epithelial ovarian carcinoma were prospectively recorded. Demographic, surgical, and pathological data as well as postoperative hospitalization events were collected. Each patient was preoperatively assessed and scored according to the American Society of Anesthesiologists (ASA). Major morbidity was defined if one of the following events occurred during the first 30 postoperative days: need for unplanned readmission, any type of complication requiring reoperation, deep venous thrombosis or thromboemboli, sepsis, or pneumonia.
Patients with stage IV or with different histological subtypes were excluded since they were not included in the original GOG study.
eligibility criteria
Inclusion criteria were as follows:
Stage IIIC primary ovarian, tubal or primary peritoneal carcinoma. Histologies included serous, endometrioid, mucinous, undifferentiated, clear cell, mixed-epithelial, transitional cell, malignant Brenner's Tumor, or adenocarcinoma not otherwise specified. RD <1 cm. Adequate renal function (creatinine £ 1.5 · institutional upper limit normal). Adequate bone marrow reserve (absolute neutrophil count ‡ 1500/ll, platelets ‡ 100 000/ll). GOG performance status of zero, one, or two.
Older age did not constitute a contraindication for eligibility for i.p. chemotherapy. In the first period (1/2006-1/2007), major large-bowel resections were considered a relative contraindication for the utilization of i.p. chemotherapy, while in 2007, we reversed this relative contraindication.
catheter placement
All patients with a presumptive diagnosis of ovarian carcinoma (on the basis of symptoms, imaging, CA125) were counseled before surgery. A discussion about potential benefits and most frequent side-effects occurred before surgery and patients were consented for i.p. port placement in cases with RD <1 cm.
At time of surgery, a small transverse incision slightly larger than the port was made in the midclavicular line, overlying the lower ribs. A s.c. pocket was then developed over the fascia covering the ribs. The catheter was tunneled under the cutaneous tissue, above the fascia, for at least 10 cm, pulled into the peritoneal cavity, and then flushed with heparin. The port was then anchored with three permanent sutures to the fascia, to prevent rotation or migration. Two types of port were used: an i.p. port with a 14.3-fenestrated catheter and an intravascular port with a single-lumen catheter.
During the postoperative stay, planning with the division of medical oncology occurred to finalize treatment plans, and the patients had another opportunity to discuss the pros and cons of i.p. chemotherapy. Table 1 . In summary, mean age was 65.6 years and performance status as defined by the ASA score was ‡3 in 60 patients (57.1%). Fortyfive patients (43%) were debulked to microscopic disease, 44 (42%) patients were debulked to visible disease <1 cm, and 16 (15%) were left with gross disease >1 cm. Twenty-one patients (20%) experienced major morbidity in the first 30 days after surgery (as defined in the 'Methods' section). An i.p. port was primarily placed in 53 of 89 (60%) eligible patients. The main reasons why a decision was made not to place a port were on the basis of both patients' performance status and type of surgical procedures carried out, and a decision was left to physician discretion. We noticed an increase in i.p. port placement during the second year of study: 13 of 34 optimally debulked patients (38%) had their port The mean interval time between surgery and chemotherapy was 33 days (range: 15-60). This mean interval was 34 days (range: 26-60) for patients who started i.p. chemotherapy, while it was 32 days (range: 13-60) for patients who started i.v. chemotherapy. This interval was 34 days on average (range: 15-60) for patients who had an i.p. port placed at primary surgery.
i.p. chemotherapy: reasons for not recommending i.p. chemotherapy was recommended in 59 of 89 (66%) cases. Reasons for not recommending i.p. chemotherapy in patients optimally debulked are summarized in Table 2 i.p. chemotherapy: reasons for not starting After i.p. chemotherapy was recommended, patients were either reevaluated within 4 weeks from the date of surgery at Mayo Clinic (if they were to receive chemotherapy at Mayo) or referred back to their referring oncologist with recommendations for treatment.
Of 59 patients for whom i.p. chemotherapy was recommended, information regarding chemotherapy was not available for four patients: these four patients were excluded from the subsequent analyses. Thirty-three of 55 patients (60%) started i.p. chemotherapy (39% of the optimally debulked population) (Figure 2) . The other 22 patients to whom i.p. chemotherapy was recommended did not start any i.p. treatment. Reasons for not starting i.p. are summarized in Table 3 and included perioperative morbidity in three patients (13.6%) including one postoperative death; slow recovery or poor performance status at time of reevaluation in six (27.3%), including four patients who redeveloped ascites or pleural original article Annals of Oncology effusions and had leakage of ascites around the port site; and referral to centers not familiar with i.p. chemotherapy for seven patients (31.8%).
All patients who started i.p. chemotherapy had their i.p. port placed at time of primary surgery, except one patient in whom the i.p. port was placed 27 days after the primary debulking.
i.p. chemotherapy: reasons for discontinuation Thirty-three of 55 patients for whom i.p. was recommended (60%) started i.p. chemotherapy (this constitutes 39% of the optimally debulked population) (Figure 2 ). Only 17 of 33 (50%) patients received three or more cycles. This number represents 31% of the population in which i.p. chemotherapy was recommended and 20% of the group of all eligible patients ( Figure 2 ). Only 12 patients of the 33 who began i.p. chemotherapy (36%) were able to successfully complete the sixcycle course (Table 3 ). This constitutes 14% of all eligible patients and 22% of the patients for whom i.p. chemotherapy was recommended (Figure 2 Reasons for discontinuation included chemotherapy-related toxic effects in 9 of 21 patients (43%). These included grade 2 nephrotoxicity in 3 of 21 (14.3%), febrile neutropenia/sepsis in 3 patients (14.3%), intolerable abdominal pain in 1 patient, and severe recurrent nausea with dehydration in 1 patient. Catheter-related toxic effects/malfunctions were the reason for discontinuing i.p. chemotherapy in 8 of 21 patients (38%). These mainly included port-site infection with cellulitis (six cases: 28.6%) requiring catheter removed. Other events included catheter erosion in the bowel with bowel perforation in one patient, catheter occlusion in one patient, and fluid leakage from the vagina in one patient. These patients all had their catheters removed. Three patients experienced progression of the disease during i.p. chemotherapy and therefore the treatment was stopped ( Table 4) . Outcomes of i.p. chemotherapy stratified by number of cycles administrated are summarized in Table 5 ; all patients who completed the six course treatment achieved a complete response to chemotherapy.
We then analyzed predictors of successful completion of three or more cycles of i.p. chemotherapy. In the subgroup of patients with RD <1 cm (n = 85 for whom follow-up was available), none of the patients with a preoperative creatinine level ‡1.2 mg/dl (n = 7), and only 2 of 34 patients >70, were able to successfully complete more than three cycles of i.p. chemotherapy. Given the small number of patients, a statistical analysis was not carried out. We did not find any correlation Figure 2 . Rates of patients for whom i.p. chemotherapy was recommended (i.p. recomm), started (i.p. started), who received at least three cycles of i.p. chemotherapy ( ‡3 cycles) and who completed the sixcycle course starting from patients who were optimally debulked with follow-up data available. Only 12/85 (14%) of the patients who were optimally debulked were able to complete the i.p. regimen as scheduled. 
discussion
In January 2006, the NCI (Bethesda) announced that i.p. chemotherapy offers a survival benefit as opposed to i.v. chemotherapy in patients with advanced OC who were able to be optimally debulked [16] on the basis of the results of three large randomized studies [8, 12, 15] . Accordingly, many oncologists in the United States adopted i.p. chemotherapy for patients with optimally debulked OC. However, many oncologists worldwide refused to adopt i.p. chemotherapy as the new standard of care. Reasons for not adopting the new regimen mainly include the following: (i) the benefit in survival is no longer evident when the i.p. regimen used in GOG 172 is compared with the actual standard of care with i.v. carboplatin and taxol and (ii) the toxicity reported in GOG 172 is higher than with i.v. carboplatin and taxol [19] .
Regarding the regimen to be administered, the NCI recommendations stated that 'while it is not possible to specify a precise regimen, the three largest studies with the greatest survival advantage delivered cisplatin 100 mg/m 2 i.p.. The two most recent trials also included taxanes.' [16] . Potential reasons and biases for the observed benefits in the i.p. arms of the three mentioned studies were not specifically addressed by the NCI recommendations [14, 17] . A survey concerning the use of i.p. chemotherapy was sent to members of the Society of Gynecologic Oncologists and to 200 members of the American Society of Clinical Oncologists to identify the regimens of i.p. chemotherapy used in women with OC [20] . Of the responders, 77% indicated that they offer i.p. chemotherapy and only 38% of these providers use a dose of cisplatin of 100 mg/m 2 . Further, 60% of these modify the regimen on the basis of age. Most of the physicians who offer i.p. chemotherapy (54%) use a dose of 75 mg/m 2 instead. Significant concerns expressed included neurologic toxic effects (55% of all responders), nausea and vomiting (51%), catheter infections (39%), and nephropathy (39%).
The GOG study initially [15] reported that 'significantly more patients in the i.p.-therapy group than in the i.v.-therapy group had severe (grade 3 or 4) fatigue, pain, or hematologic, gastrointestinal, metabolic, or neurologic toxic effect'. These included 19% of grade 3/4 neurotoxicity, 7% of renal/ genitourinary events, 16% of infections, and 27% of metabolic events. Rates of completion of the i.p. treatment and reasons for discontinuation were primarily assessed in a different manuscript [21] . Only 42% of the patients were able to successfully complete six cycles of chemotherapy. In our study, only 52% (17/33) of the patients were able to complete three or more cycles with only 36% (12/33) of the patients who were started on i.p. chemotherapy able to complete the six cycles course. Considering the larger group of eligible patients who were recommended to receive i.p. chemotherapy in our cohort, only 31% were able to receive three or more cycles and 22% were able to successfully complete their six-course i.p. chemotherapy.
Our cohort highlights the realities encountered when applying guidelines derived from randomized studies to the general population. Though Mayo Clinic is a tertiary care center, the majority of our patients are regional and local patients and represent a cross-section of the OC population. Randomization for GOG 172 was done after surgery, when patients had recovered from their surgery and those with the best performance status and without complication could be [20, 21] . Additionally, we recognize that changing patterns of treatment delivery within a center takes time to overcome personal biases: the fact that we observed increased rates of administration in year 2 of the study attests to that. We hypothesized that physician's awareness and comfort in administrating i.p. chemotherapy as well as the increased rate of port placed during the second year gave an important contribution in this result. We conclude that there is definitely a learning curve in administering i.p. chemotherapy as well shown by Figure 3 . A better management of complications and toxic effects due to the knowledge accumulated with time led in fact to a more successful completion rate during the second year.
Reasons for discontinuation were analyzed in the GOG 172 study [22] . They were stratified in three categories: (i) catheter related constituted 34% of the reasons of discontinuation; (ii) not catheter related, including nausea, vomiting, dehydration, and renal/metabolic disturbances, accounting for 29% of the patients; and (iii) possibly i.p. treatment related, including major bowel complications, infections, abdominal pain, or patient refusal, accounting for 38% of the discontinuations. In our study, three patients were discontinued because of grade 1-2 nephrotoxicity. None of these patients had pre-existing diabetes or renal function abnormalities and all received the treatment in the inpatient setting. Pre-and post-treatment hydration was administered with each cycle. Three patients were discontinued because of febrile neutropenia/sepsis. We believe that both these complications are primarily related to the high dose of cisplatin (100 mg/m 2 ) administered i.p. We hypothesize that the reason why our rate of nephrotoxicity was markedly higher than the original report [15] is that in the original study, renal toxicity and metabolic events were considered two distinct categories but could both contain patients with renal toxicity. Port infection or malfunction as well as severe abdominal pain related to i.p. chemotherapy administration constitute the other main reasons of discontinuation. These were not related to different types of port used, confirming the results of the GOG 172 [22] . Age also has to be considered a risk factor for discontinuation of this regimen of therapy: only three patients >70 and no patients with a preoperative creatinine level ‡1.2 mg/dl were able to receive more than three cycles of chemotherapy.
As a result of our experiences, in 2008, we revised our strategy for delivery of primary chemotherapy to improve compliance, decrease toxicity, and retain eligibility for ongoing randomized phase III studies. The inclusion criteria for port placement at primary surgery and subsequent i.p. therapy and the regimen used are as follows: (i) stage III epithelial cancer (tubal, ovarian, primary peritoneal), (ii) optimal debulking, (iii) age £ 70 years, (iv) preoperative normal renal function with an estimated glomerular filtration rate > 60, (v) Strengths of the present study consist in the fact that this is a consecutive cohort of patients prospectively followed. Furthermore, patients were surgically treated in a tertiary center with the vast majority receiving their chemotherapy in the same center. The treatment followed the protocol and the dosage that was shown to be superior to i.v. treatment in the GOG 172 study and recommended by National Institutes of Health. Further, the inpatient protocol allowed a strict observation of the patients with adequate hydration and supportive care when needed.
Limitations of the present study include the relatively small number of patients who were able to start i.p. chemotherapy. At the same time, we acknowledge that expertise and confidence in using i.p. chemotherapy has evolved with time. Another limitation resides in the comparison with the large randomized study. Although the rates of complications are slightly higher and the completion rate is slightly lower, we acknowledge that our cohort is older than the one reported in the original trial. However, this is an expected scenario of most phase III studies in OC when applied to the general population. We also observed an increased number of i.p. ports placed during the second year as well as a higher completion rate of the six cycles of i.p. chemotherapy. Nevertheless, in our opinion, the toxicity related to the i.p. regimen as reported in GOG 172 appears to be too high, even when this regimen is used in a tertiary center, adopting adequate measures for monitoring and following the patients during the chemotherapy period.
Further studies adopting less toxic regimens with higher acceptability are warranted. These should be compared with the standard i.v. treatment in order to avoid similar controversies in adapting the results as occurred after GOG 172. Furthermore, identification of the factors to identify (pretreatment) those patients at highest risk for major sideeffects and complications of therapy should be an object of further investigations. 
